يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Kymera Therapeutics, Inc. +1.04%
Kymera Therapeutics, Inc. KYMR | 87.40 | +1.04% |
Kymera Therapeutics (NASDAQ:KYMR) underwent analysis by 25 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 12 | 13 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 7 | 9 | 0 | 0 | 0 |
| 3M Ago | 3 | 3 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $108.76, with a high estimate of $138.00 and a low estimate of $69.00. This upward trend is evident, with the current average reflecting a 45.09% increase from the previous average price target of $74.96.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kymera Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jeet Mukherjee | BTIG | Maintains | Buy | $138.00 | $138.00 |
| Kalpit Patel | B. Riley Securities | Raises | Buy | $117.00 | $80.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $103.00 | $70.00 |
| Sudan Loganathan | Stephens & Co. | Raises | Overweight | $110.00 | $65.00 |
| Joseph Catanzaro | Mizuho | Raises | Outperform | $120.00 | $81.00 |
| Brian Cheng | JP Morgan | Raises | Overweight | $125.00 | $70.00 |
| Kelly Shi | Jefferies | Raises | Buy | $122.00 | $73.00 |
| Geoff Meacham | Citigroup | Raises | Buy | $110.00 | $80.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $116.00 | $69.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $116.00 | $80.00 |
| Jeff Jones | Oppenheimer | Raises | Outperform | $120.00 | $67.00 |
| James Quigley | Morgan Stanley | Raises | Overweight | $127.00 | $73.00 |
| Etzer Darout | Barclays | Raises | Overweight | $119.00 | $70.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $125.00 | $98.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $134.00 | $84.00 |
| Faisal Khurshid | Leerink Partners | Raises | Outperform | $118.00 | $70.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $112.00 | $71.00 |
| Jeet Mukherjee | BTIG | Raises | Buy | $138.00 | $75.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $80.00 | $68.00 |
| Etzer Darout | Barclays | Raises | Overweight | $70.00 | $60.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $69.00 | $53.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $84.00 | $70.00 |
| Brad Canino | Guggenheim | Announces | Buy | $90.00 | - |
| Jeet Mukherjee | BTIG | Raises | Buy | $75.00 | $59.00 |
| Joseph Catanzaro | Mizuho | Announces | Outperform | $81.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kymera Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Kymera Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Kymera Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Kymera Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Kymera Therapeutics analyst ratings.
Discovering Kymera Therapeutics: A Closer Look
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Financial Insights: Kymera Therapeutics
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Kymera Therapeutics's revenue growth over a period of 3M has faced challenges. As of 30 September, 2025, the company experienced a revenue decline of approximately -26.12%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Kymera Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -2973.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kymera Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -8.57%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Kymera Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Kymera Therapeutics's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
